Ocular rosacea

Ocular Surface

Volumn 3, Issue 1, 2005, Pages 41-58

  Alvarenga, Lenio S ^a,b   Mannis, Mark J ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c NONE   (United States)

Author keywords

Blepharitis; Demodex folliculorum; Helicobacter pylori; Inflammatory disorders; Keratitis; Metronidazole; Ocular inflammation; Ocular rosacea; Ocular surface; Rosacea; Tears; Tetracyclines

Indexed keywords

AMPICILLIN; ANTIINFLAMMATORY AGENT; AUTACOID; AZELAIC ACID; BENZOYL PEROXIDE; CLARITHROMYCIN; CLINDAMYCIN; CLONIDINE; CORTICOSTEROID DERIVATIVE; DICLOFENAC; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR; ERYTHROMYCIN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 8; KETOROLAC; LUBRICATING AGENT; MATRIX METALLOPROTEINASE; METRONIDAZOLE; MINOCYCLINE; OMEPRAZOLE; OXYTETRACYCLINE; RETINOID DERIVATIVE; RILMENIDINE; TETRACYCLINE DERIVATIVE; TRIACYLGLYCEROL LIPASE; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE DISEASE; BACTERIAL FLORA; CHRONIC INFLAMMATION; CLINICAL FEATURE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CORNEA DISEASE; CORNEA VASCULARIZATION; DEMODEX; DISEASE CLASSIFICATION; EPISCLERITIS; ERYTHEMA; EYE DISEASE; EYE IRRITATION; EYELID DISEASE; FLUSHING; GENETIC PREDISPOSITION; HELICOBACTER PYLORI; HUMAN; HYGIENE; IMMUNOMODULATION; INCIDENCE; MEIBOMIAN GLAND; META ANALYSIS; PAPULE; PATHOGENESIS; PHOTOSENSITIVITY DISORDER; PREVALENCE; PROTEIN EXPRESSION; REVIEW; SCLERA DISEASE; SEBACEOUS GLAND DISEASE; SIDE EFFECT; SKIN DISEASE; TEAR FILM; TELANGIECTASIA; TOOTH COLOR; VASCULAR DISEASE; VISUAL DISORDER; XEROSTOMIA;

EID: 14844310211     PISSN: 15420124     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-0124(12)70121-0     Document Type: Article

References (197)

1. Lindow KB, Warren C. Understanding rosacea. A guide to facilitating care. Am J Nurs 2001;101:44-51; quiz 52
2. Cowan MA. Rosacea and its treatment. Trans Ophthalmol Soc U K 1966;86:719-25
3. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002;46:584-7
4. Ghanem VC, Mehra N, Wong S, Mannis MJ. The prevalence of ocular signs in acne rosacea: comparing patients from ophthalmology and dermatology clinics. Cornea 2003;22:230-3
5. Grosshans E. [Rosacea]. Presse Med 1988;17:2393-8
6. Akpek EK, Merchant A, Pinar V, Foster CS. Ocular rosacea: patient characteristics and follow-up. Ophthalmology 1997;104:1863-7
7. Browning DJ, Proia AD. Ocular rosacea. Surv Ophthalmol 1986;31:145-58
8. Nazir SA, Murphy S, Siatkowski RM, et al. Ocular rosacea in childhood. Am J Ophthalmol 2004;137:138-44
9. Zuber TJ. Rosacea. Prim Care 2000;27:309-18
10. Zuber TJ. Rosacea: beyond first blush. Hosp Pract (Off Ed) 1997;32:188-9
11. Berg M, Liden S. An epidemiological study of rosacea. Acta Derm Venereol 1989;69:419-23
12. Borrie P. Rosacea with special reference to its ocular manifestations. Br J Dermatol 1953;65:458-63
13. Starr PA. Oculocutaneous aspects of rosacea. Proc R Soc Med 1969;62:9-11
14. Quarterman MJ, Johnson DW, Abele DC, et al. Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with doxycycline. Arch Dermatol 1997;133:49-54
15. Michel JL, Cabibel F. [Frequency, severity and treatment of ocular rosacea during during cutaneous rosacea]. Ann Dermatol Venereol 2003;130:20-24
16. Roper-Hall MJ. The ocular aspects of rosacea. Trans Ophthalmol Soc U K 1966;86:727-32
17. Gudmundsen KJ, O'Donnell BF, Powell FC. Schirmer testing for dry eyes in patients with rosacea. J Am Acad Dermatol 1992;26:211-4
18. Sibenge S, Gawkrodger DJ. Rosacea: a study of clinical patterns, blood flow, and the role of Demodex folliculorum. J Am Acad Dermatol 1992;26:590-3
19. Donshik PC, Hoss DM, Ehlers WH. Inflammatory and papulosquamous disorders of the skin and eye. Dermatol Clin 1992;10:533-47
20. Knox CM, Smolin G. Rosacea. Int Ophthalmol Clin 1997;37:29-40
21. Tisma VS, Basta-Juzbasic A, Dobric I, et al. Etiopathogenesis, classification, and current trends in treatment of rosacea. Acta Dermatovenerol. Croat 2003;11:236-46
22. Bourrat E, Rybojad M, Deplus S,Morel P. [Rosacea with ocular involvement in a child]. Ann Dermatol Venereol 1996;123:664-5
23. Erzurum SA, Feder RS, Greenwald MJ. Acne rosacea with keratitis in childhood. Arch Ophthalmol 1993;111:228-230
24. Drolet B, Paller AS. Childhood rosacea. Pediatr Dermatol 1992;9:22-6
25. Zengin N, Tol H, Gunduz K, et al. Meibomian gland dysfunction and tear film abnormalities in rosacea. Cornea 1995;14:144-6
26. Landow K. Unraveling the mystery of rosacea. Keys to getting the red out. Postgrad Med 2002;112:51-8, 82; quiz 59
27. Plewig G, Kligman AM. Rosacea, in Plewig G, Kligman AM (eds): Acne and rosacea. New York, Springer-Verlag, 1993, pp 433-42
28. Wise G. Ocular rosacea. Am J Ophthalmol 1943;26:591-609
29. Macsai MS, Mannis M, Huntley AC: Acne rosacea, in Mannis M, Macsai MS, Huntley AC (eds): Eye and skin disease. Philadelphia, Lippincott-Raven, 1996, pp 335-41
30. Higgins E, du Vivier A. Alcohol intake and other skin disorders. Clin Dermatol 1999;17:437-41
31. Blount BW, Pelletier AL. Rosacea: a common, yet commonly overlooked, condition. Am Fam Physician 2002;66:435-40
32. Webster GF. Acne vulgaris and rosacea: evaluation and management. Clin Cornerstone 2001;4:15-22
33. Gubisch W. [Otophyma - a rare disease]. HNO 1983;31:56-8
34. Jansen T, Plewig G. Clinical and histological variants of rhinophyma, including nonsurgical treatment modalities. Facial Plast Surg 1998;14:241-53
35. Barankin B, Guenther L. Rosacea and atopic dermatitis. Two common oculocutaneous disorders. Can Fam Physician 2002;48:721-4
36. Yaylali V, Ozyurt C. Comparison of tear function tests and impression cytology with the ocular findings in acne rosacea. Eur J Ophthalmol 2002;12:11-7
37. Faraj HG, Hoang-Xuan T. Chronic cicatrizing conjunctivitis. Curr Opin Ophthalmol 2001;12:250-7
38. Tanzi EL, Weinberg JM. The ocular manifestations of rosacea. Cutis 2001;68:112-4
39. Chen DM, Crosby DL. Periorbital edema as an initial presentation of rosacea. J Am Acad Dermatol 1997;37:346-8
40. Jenkins MS, Brown SI, Lempert SL, Weinberg RJ. Ocular rosacea. Am J Ophthalmol 1979;88(3 Pt 2):618-22
41. Driver PJ, Lemp MA. Meibomian gland dysfunction. Surv Ophthalmol 1996;40:343-67
42. Hom MM, Martinson JR, Knapp LL, Paugh JR. Prevalence of Meibomian gland dysfunction. Optom Vis Sci 1990;67:710-2
43. Ong BL. Relation between contact lens wear and meibomian gland dysfunction. Optom Vis Sci 1996;73:208-10
44. Hoang-Xuan T, Rodriguez A, Zaltas MM, et al. Ocular rosacea. A histologic and immunopathologic study. Ophthalmology 1990;97:1468-75
45. Albert DL, Brownstein S, Jackson WB. Conjunctival granulomas in rosacea. Am J Ophthalmol 1992;113:108-10
46. Blaustein BH, Gurwood AS. Recurrent phlyctenular keratoconjunctivitis: a forme fruste manifestation of rosacea. Optometry 2001;72:179-84
47. Culbertson WW, Huang AJ, Mandelbaum SH, et al. Effective treatment of phlyctenular keratoconjunctivitis with oral tetracycline. Ophthalmology 1993;100:1358-66
48. Dursun D, Piniella AM, Pflugfelder SC. Pseudokeratoconus caused by rosacea. Cornea 2001;20:668-9
49. Hope-Ross MW, Chell PB, Kervick GN, McDonnell PJ. Recurrent corneal erosion: clinical features. Eye 1994;8(Pt 4):373-377
50. Kocak-Altintas AG, Kocak-Midillioglu I, Gul U, et al. Impression cytology and ocular characteristics in ocular rosacea. Eur J Ophthalmol 2003;13:351-9
51. Lemp MA, Mahmood MA, Weiler HH. Association of rosacea and keratoconjunctivitis sicca. Arch Ophthalmol 1984;102:556-7
52. Millikan L. The proposed inflammatory pathophysiology of rosacea: implications for treatment. Skinmed 2003;2:43-7
53. Millikan LE. Rosacea as an inflammatory disorder: a unifying theory? Cutis 2004;73:5-8
54. Bamford JT. Rosacea: current thoughts on origin. Semin Cutan Med Surg 2001;20:199-206
55. McStay MK, Caplin ME. Carcinoid tumour. Minerva Med 2002;93:389-401
56. Lips CJ, Lentjes EG, Hoppener JW. The spectrum of carcinoid tumours and carcinoid syndromes. Ann Clin Biochem 2003;40:612-27
57. Wilkin JK. Rosacea. Pathophysiology and treatment. Arch Dermatol 1994;130:359-62
58. Findlay GH, Simson IW. Leonine hypertrophic rosacea associated with a benign bronchial carcinoid tumour. Clin Exp Dermatol 1977;2:175-6
59. Marks R, Harcourt-Webster JN. Histopathology of rosacea. Arch Dermatol 1969;100:683-91
60. Marks R. Histogenesis of the inflammatory component of rosacea. Proc R Soc Med 1973;66:742-5
61. Borrie P. The state of the blood vessels of the face in rosacea. Part I. Br J Dermatol 1955;67:5-8
62. Borrie P. The state of the blood vessels of the face in rosacea. Part II. Br J Dermatol 1955;67:73-75
63. Wilkin JK, Josephs JA. Infrared photographic studies of rosacea. Arch Dermatol 1980;116:676-8
64. Tan SG, Cunliffe WJ. Rosacea and migraine. Br Med J 1976;1:21
65. Berg M. Facial skin complaints and work at visual display units. Epidemiological, clinical and histopathological studies. Acta Derm Venereol Suppl (Stockh) 1989;150:1-40
66. Berg M, Liden S. Postmenopausal female rosacea patients are more disposed to react with migraine. Dermatology 1996;193:73-74
67. Guarrera M, Parodi A, Cipriani C, et al. Flushing in rosacea: a possible mechanism. Arch Dermatol Res 1982;272:311-6
68. Dahl MV. Pathogenesis of rosacea. Adv Dermatol 2001;17:29-45
69. Wilkin JK. Effect of subdepressor clonidine on flushing reactions in rosacea. Change in malar thermal circulation index during provoked flushing reactions. Arch Dermatol 1983;119:211-4
70. Grosshans E, Michel C, Arcade B, Cribier B. [Rilmenidine in rosacea: a double-blind study versus placebo]. Ann Dermatol Venereol 1997;124:687-91
71. Wilkin JK. Effect of nadolol on flushing reactions in rosacea. J Am Acad Dermatol 1989;20:202-5
72. Bernstein JE, Soltani K. Alcohol-induced rosacea flushing blocked by naloxone. Br J Dermatol 1982;107:59-61
73. Neumann E, Frithz A. Capillaropathy and capillaroneogenesis in the pathogenesis of rosacea. Int J Dermatol 1998;37:263-6
74. Burton JL, Pye RJ, Meyrick G, Shuster S. The sebum excretion rate in rosacea. Br J Dermatol 1975;92:541-3
75. Aloi F, Tomasini C, Soro E, Pippione M. The clinicopathologic spectrum of rhinophyma. J Am Acad Dermatol 2000;42:468-72
76. Mathers WD, Lane JA. Meibomian gland lipids, evaporation, and tear film stability. Adv Exp Med Biol 1998;438:349-60
77. Paranjpe DR, Foulks GN. Therapy for meibomian gland disease. Ophthalmol Clin North Am 2003;16:37-42
78. Shine WE, McCulley JP, Pandya AG. Minocycline effect on meibomian gland lipids in meibomianitis patients. Exp Eye Res 2003;76:417-20
79. Shine WE, McCulley JP. Meibomian gland triglyceride fatty acid differences in chronic blepharitis patients. Cornea 1996;15:340-6
80. Schaur RJ, Dussing G, Kink E, et al. The lipid peroxidation product 4-hydroxynonenal is formed by - and is able to attract - rat neutrophils in vivo. Free Radic Res 1994;20:365-73
81. Li Y, Ferrante A, Poulos A, Harvey DP. Neutrophil oxygen radical generation. Synergistic responses to tumor necrosis factor and mono/polyunsaturated fatty acids. J Clin Invest 1996;97:1605-9
82. Dougherty JM, McCulley JP. Bacterial lipases and chronic blepharitis. Invest Ophthalmol Vis Sci 1986;27:486-91
83. Ta CN, Shine WE, McCulley JP, et al. Effects of minocycline on the ocular flora of patients with acne rosacea or seborrheic blepharitis. Cornea 2003;22:545-8
84. Georgala S, Katoulis AC, Kylafis GD, et al. Increased density of Demodex folliculorum and evidence of delayed hypersensitivity reaction in subjects with papulopustular rosacea. J Eur Acad Dermatol Venereol 2001;15:441-4
85. el-Shazly AM, Ghaneum BM, Morsy TA, Aaty HE. The pathogenesis of Demodex folliculorum (hair follicular mites) in females with and without rosacea. J Egypt Soc Parasitol 2001;31:867-75
86. Ayres S Jr, Ayres S 3rd. Demodectic eruptions (demodicidosis) in the human. 30 years' experience with 2 commonly unrecognized entities: pityriasis folliculorum (Demodex) and acne rosacea (Demodex type). Arch Dermatol 1961;83:816-27
87. Hojyo Tomoka MT, Dominguez Soto L. [Demodecidosis and rosaceiform dermatitis]. Med Cutan Ibero Lat Am 1976;4:83-90
88. Morgan RJ, Coston TO. Demodex blepharitis. South Med J 1964;57:694-9
89. Rufli T, Mumcuoglu Y, Cajacob A, Buchner S. [Demodex folliculorum: aetiopathogenesis and therapy of rosacea and perioral dermatitis (author's transl)]. Dermatologica 1981;162:12-26
90. Roihu T, Kariniemi AL. Demodex mites in acne rosacea.J Cutan Pathol 1998;25:550-2
91. Erbagci Z, Ozgoztasi O. The significance of Demodex folliculorum density in rosacea. Int J Dermatol 1998;37:421-5
92. Abd-El-Al AM, Bayoumy AM, Abou Salem EA. A study on Demodex folliculorum in rosacea. J Egypt Soc Parasitol 1997;27:183-95
93. Bonnar E, Eustace P, Powell FC. The Demodex mite population in rosacea. J Am Acad Dermatol 1993;28:443-8
94. Ramelet AA, Perroulaz G. [Rosacea: histopathologic study of 75 cases]. Ann Dermatol Venereol 1988;115:801-6
95. Forton F. Seys B. Density of Demodex folliculorum in rosacea: a case-control study using standardized skin-surface biopsy. Br J Dermatol 1993;128:650-9
96. Rebora A. The management of rosacea. Am J Clin Dermatol 2002;3:489-96
97. Kocak M, Yagli S, Vahapoglu G, Eksioglu M. Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study. Dermatology 2002;205:265-70
98. Forton F. Demodex and perifollicular inflammation in man. Review and report of 69 biopsies. Ann Dermatol Venereol 1986;113:1047-58
99. Huismans H. [Demodex folliculorum]. Klin Monatsbl Augenheilkd 1988;193:304-6
100. Gutgesell VJ, Stern GA, Hood CI. Histopathology of meibomian gland dysfunction. Am J Ophthalmol 1982;94:383-7
101. Clifford CW, Fulk GW. Association of diabetes, lash loss, and Staphylococcus aureus with infestation of eyelids by Demodex folliculorum (Acari: Demodicidae). J Med Entomol 1990;27:467-70
102. Morfin Maciel BM. [Demodicidosis in a female patient treated as allergic blepharoconjunctivitis]. Reporte de un caso. Rev Alerg Mex 2003;50:232-6
103. Barnhorst DA Jr, Foster JA, Chern KC, Meisler DM. The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology 1996;103:1880-3
104. Forton F, Seys B, Marchal JL, Song AM. Demodex folliculorum and topical treatment: acaricidal action evaluated by standardized skin surface biopsy. Br J Dermatol 1998;138:461-6
105. Akamatsu H, Oguchi M, Nishijima S, et al. The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne. Arch Dermatol Res 1990;282:449-54
106. Akamatsu H, Horio T. The possible role of reactive oxygen species generated by neutrophils in mediating acne inflammation. Dermatology 1998;196:82-5
107. Rebora A, Drago F. Helicobacter pylori and rosacea. J Am Acad Dermatol 2000;43(5 Pt 1):884. Erratum in J Am Acad Dermatol 2001;45:960
108. Szlachcic A. The link between Helicobacter pylori infection and rosacea. J Eur Acad Dermatol Venereol 2002;16:328-33
109. Gurer MA, Erel A, Erbas D, et al. The seroprevalence of Helicobacter pylori and nitric oxide in acne rosacea. Int J Dermatol 2002;41:768-70
110. Rebora A, Drago F, Picciotto A. Helicobacter pylori in patients with rosacea. Am J Gastroenterol 1994;89:1603-4
111. Diaz C, O'Callaghan CJ, Khan A, Ilchyshyn A. Rosacea: a cutaneous marker of Helicobacter pylori infection? Results of a pilot study. Acta Derm Venereol 2003;83:282-6
112. Cohen H. Peptic ulcer and Helicobacter pylori. Gastroenterol Clin North Am 2000;29:775-89
113. Franceschi F, Gasbarrini A, Fontana L. Role of Helicobacter pylori infection in ophthalmology. Ophthalmology 1998;105:1351-2
114. Mindel JS, Rosenberg EW. Is Helicobacter pylori of interest to ophthalmologists? Ophthalmology 1997;104:1729-30
115. Szlachcic A, Sliwowski Z, Karczewska E, et al. Helicobacter pylori and its eradication in rosacea. J Physiol Pharmacol 1999;50:777-86
116. Rebora A, Drago F, Parodi A. May Helicobacter pylori be important for dermatologists? Dermatology 1995;191:6-8
117. Chen TS, Chang FY, Chen PC, et al. Simplified 13C-urea breath test with a new infrared spectrometer for diagnosis of Helicobacter pylori infection. J Gastroenterol Hepatol 2003; 18:1237-43
118. Israeli E, Ilan Y, Meir SB, et al. A novel 13C-urea breath test device for the diagnosis of Helicobacter pylori infection: continuous online measurements allow for faster test results with high accuracy. J Clin Gastroenterol 2003;37:139-41
119. Oshima H, Kajiwara M. [13C-urea breath test]. Nippon Rinsho 2003;61:67-71
120. Hegedus O, Ryden J, Rehnberg AS, et al. Validated accuracy of a novel urea breath test for rapid Helicobacter pylori detection and in-office analysis. Eur J Gastroenterol Hepatol 2002;14:513-20
121. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed 2003;2:234-45
122. von Szily A. Zur klinik und pathologischen Anatomie der Rosazea des Auges. Klin Monatsbl Augenheilkd 1929;82:577-92
123. Barton K, Monroy DC, Nava A, Pflugfelder SC. Inflammatory cytokines in the tears of patients with ocular rosacea. Ophthalmology 1997;104:1868-74
124. Pisella PJ, Brignole F, Debbasch C, et al. Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca. Ophthalmology 2000;107:1841-9
125. Perry HD, Donnenfeld ED. Dry eye diagnosis and management in 2004. Curr Opin Ophthalmol 2004;15:299-304
126. Wilson SE, He YG, Lloyd SA. EGF, EGF receptor, basic FGF, TGF beta-1, and IL-1 alpha mRNA in human corneal epithelial cells and stromal fibroblasts. Invest Ophthalmol Vis Sci 1992;33:1756-65
127. Wilson SE, Schultz GS, Chegini N, et al. Epidermal growth factor, transforming growth factor alpha, transforming growth factor beta, acidic fibroblast growth factor, basic fibroblast growth factor, and interleukin-1 proteins in the cornea. Exp Eye Res 1994;59:63-71
128. Dinarello CA. Modalities for reducing interleukin 1 activity in disease. Trends Pharmacol Sci 1993;14:155-9
129. Li DQ, Lokeshwar BL, Solomon A, et al. Regulation of MMP-9 production by human corneal epithelial cells. Exp Eye Res 2001;73:449-59
130. Li Q, Fukuda K, Lu Y, et al. Enhancement by neutrophils of collagen degradation by corneal fibroblasts. J Leukoc Biol 2003;74:412-9
131. Girard MT, Matsubara M, Fini ME. Transforming growth factor-beta and interleukin-1 modulate metalloproteinase expression by corneal stromal cells. Invest Ophthalmol Vis Sci 1991;32:2441-54
132. Yamada J, Dana MR, Sotozono C, Kinoshito S. Local suppression of IL-1 by receptor antagonist in the rat model of corneal alkali injury. Exp Eye Res 2003;76:161-7
133. Boisjoly HM, Laplante C, Bernatchez SF, et al. Effects of EGF, IL-1 and their combination on in vitro corneal epithelial wound closure and cell chemotaxis. Exp Eye Res 1993;57:293-300
134. Wilson SE, Liu JJ, Mohan RR. Stromal-epithelial interactions in the cornea. Prog Retin Eye Res 1999;18:293-309
135. Solomon A, Dursun D, Liu Z, et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 2001;42:2283-92
136. Barton K, Nava A, Monroy DC, et al. Cytokines and tear function in ocular surface disease. Adv Exp Med Biol 1998;438:461-9
137. Stone DU, Chodosh J. Oral tetracyclines for ocular rosacea: an evidence-based review of the literature. Cornea 2004;23:106-9
138. Solomon A, Rosenblatt M, Li DQ, et al. Doxycycline inhibition of interleukin-1 in the corneal epithelium. Invest Ophthalmol Vis Sci 2000;41:2544-57
139. Afonso AA, Monroy D, Stern ME, et al. Correlation of tear fluorescein clearance and Schirmer test scores with ocular irritation symptoms. Ophthalmology 1999;106:803-10
140. Schafer M, Carter L, Stein C. Interleukin 1 beta and corticotropin-releasing factor inhibit pain by releasing opioids from immune cells in inflamed tissue. Proc Natl Acad Sci U S A 1994;91:4219-23
141. De Saint Jean M, Brignole F, Feldmann G, et al. Interferon-gamma induces apoptosis and expression of inflammation-related proteins in Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999;40:2199-212
142. Ye S, Humphries S, Henney A. Matrix metalloproteinases: implication in vascular matrix remodelling during atherogenesis. Clin Sci (Lond) 1998;94:103-10
143. Kieseier BC, Seifert T, Giovannoni G, et al. Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology 1999;53:20-5
144. Afonso AA, Sobrin L, Monroy DC, et al. Tear fluid gelatinase B activity correlates with IL-1alpha concentration and fluorescein clearance in ocular rosacea. Invest Ophthalmol Vis Sci 1999;40:2506-12
145. Virtanen T, Konttinen YT, Honkanen N, et al. Tear fluid plasmin activity of dry eye patients with Sjogren's syndrome. Acta Ophthalmol Scand 1997;75:137-41
146. Sakata M, Sack RA, Sathe S, et al. Polymorphonuclear leukocyte cells and elastase in tears. Curr Eye Res 1997;16:810-9
147. Fini ME, Cook JR, Mohan R. Proteolytic mechanisms in corneal ulceration and repair. Arch Dermatol Res 1998;290 Suppl:S12-23
148. Fini ME, Parks WC, Rinehart WB, et al. Role of matrix metalloproteinases in failure to re-epithelialize after corneal injury. Am J Pathol 1996;149:1287-302
149. Leonardi A, Borghesan F, Faggian D, et al. Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. Am J Ophthalmol 2000;129:151-8
150. Kijlstra A, Jeurissen SH, Koning KM. Lactoferrin levels in normal human tears. Br J Ophthalmol 1983;67:199-202
151. Caccavo D, Pellegrino NM, Altamura M, et al. Antimicrobial and immunoregulatory functions of lactoferrin and its potential therapeutic application. J Endotoxin Res 2002;8:403-417
152. Fust A, Veres A, Kiszel P, et al. Changes in tear protein pattern after photorefractive keratectomy. Eur J Ophthalmol 2003;13:525-31
153. Kiratli H, Irkec M, Orhan M. Tear lactoferrin levels in chronic meibomitis associated with acne rosacea. Eur J Ophthalmol 2000;10:11-4
154. Schoenwald RD, Vidvauns S, Wurster DE, et al. The role of tear proteins in tear film stability in the dry eye patient and in the rabbit. Adv Exp Med Biol 1998;438:391-400
155. van Zuuren E, Graber M, Hollis S, et al. Interventions for rosacea. Cochrane Database Syst Rev 2004;1:CD003262
156. Nielsen PG. Treatment of rosacea with 1% metronidazole cream. A double-blind study. Br J Dermatol 1983;108:327-32
157. Bleicher PA, Charles JH, Sober AJ. Topical metronidazole therapy for rosacea. Arch Dermatol 1987;123:609-14
158. Breneman DL, Stewart D, Hevia O, et al. A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis 1998;61:44-7
159. Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol 1998;134:679-83
160. Jorizzo JL, Lebwohl M, Tobey RE. The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial. J Am Acad Dermatol 1998;39:502-4
161. Bjerke R, Fyrand O, Graupe K. Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulopustular rosacea. Acta Derm Venereol 1999;79:456-9
162. Bamford JT, Tilden RL, Blankush JL, Gangeness DE. Effect of treatment of Helicobacter pylori infection on rosacea. Arch Dermatol 1999;135:659-63
163. Montes LF, Cordero AA, Kriner J, et al. Topical treatment of acne rosacea with benzoyl peroxide acetone gel. Cutis 1983;32:185-90
164. Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol 1966;78:649-52
165. Marks R, Ellis J. Comparative effectiveness of tetracycline and ampicillin in rosacea. A controlled trial. Lancet 1971;2:1049-52
166. Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet 1976;1:1211-2
167. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol 1999;40:961-5
168. Saihan EM, Burton JL. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Dermatol 1980;102:443-5
169. Nielsen PG. The relapse rate for rosacea after treatment with either oral tetracycline or metronidazole cream. Br J Dermatol 1983;109:122
170. Veien NK, Christiansen JV, Hjorth N, Schmidt H. Topical metronidazole in the treatment of rosacea. Cutis 1986;38:209-10
171. Bartholomew RS, Reid BJ, Cheesbrough MJ, et al. Oxytetracycline in the treatment of ocular rosacea: a double-blind trial. Br J Ophthalmol 1982;66:386-8
172. Pflugfelder SC, Solomon A, Dursun D, Li DQ. Dry eye and delayed tear clearance: "a call to arms." Adv Exp Med Biol 2002;506:739-743
173. Nagymihalyi A, Dikstein S, Tiffany JM. The influence of eyelid temperature on the delivery of meibomian oil. Exp Eye Res 2004;78:367-70
174. Goto E, Endo K, Suzuki A, et al. Improvement of tear stability following warm compression in patients with meibomian gland dysfunction. Adv Exp Med Biol 2002;506:1149-52
175. Goto E, Monden Y, Takano Y, et al. Treatment of non-inflamed obstructive meibomian gland dysfunction by an infrared warm compression device. Br J Ophthalmol 2002;86:1403-7
176. Mori A, Oguchi Y, Goto E, et al. Efficacy and safety of infrared warming of the eyelids. Cornea 1999;18:188-93
177. Craig JP, Blades K, Patel S. Tear lipid layer structure and stability following expression of the meibomian glands. Ophthalmic Physiol Opt 1995;15:569-74
178. RongÈ L. Breaking the blepharitis cycle. EyeNet 2004;8:25-6
179. Bannatyne RM. Metronidazole, its bioactive metabolites and acne. Curr Med Res Opin 1999;15:298-9
180. Guidera AC, Luchs JI, Udell IJ. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology 2001;108:936-44
181. Sadowski T, Steinmeyer J. Effects of tetracyclines on the production of matrix metalloproteinases and plasminogen activators as well as of their natural inhibitors, tissue inhibitor of metalloproteinases-1 and plasminogen activator inhibitor-1. Inflamm Res 2001;50:175-82
182. Dougherty JM, McCulley JP, Silvany RE, Meyer DR. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci. Invest Ophthalmol Vis Sci 1991;32:2970-5
183. Thong YH. Immunomodulation by antimicrobial drugs. Med Hypotheses 1982;8:361-70
184. Frucht-Pery J, Sagi E, Hemo I, Ever-Hadni P. Efficacy of doxycycline and tetracycline in ocular rosacea. Am J Ophthalmol 1993;116:88-92
185. Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: an overview. Semin Arthritis Rheum 1999;28:392-7
186. Morrow GL, Abbott RL. Minocycline-induced scleral, dental, and dermal pigmentation. Am J Ophthalmol 1998;125:396-7
187. Fraunfelder FT, Randall JA. Minocycline-induced scleral pigmentation. Ophthalmology 1997;104:936-8
188. Bradfield YS, Robertson DM, Salomao DR, et al. Minocycline-induced ocular pigmentation. Arch Ophthalmol 2003;121:144-5
189. Duteil I, Queille-Roussel C, Rougier A, et al. High protective effect of a broad-spectrum sunscreen against tetracycline phototoxicity. Eur J Dermatol 2002;12:X-XI
190. Torresani C. Clarithromycin: a new perspective in rosacea treatment. Int J Dermatol 1998;37:347-9
191. Torresani C, Pavesi A, Manara GC. Clarithromycin versus doxyclycline in the treatment of rosacea. Int J Dermatol 1997;36:942-6
192. Fraunfelder FW. Ocular side effects associated with isotretinoin. Drugs Today (Barc) 2004;40:23-7
193. Bozkurt B, Irkec MT, Atakan N, et al. Lacrimal function and ocular complications in patients treated with systemic isotretinoin. Eur J Ophthalmol 2002;12:173-6
194. Egger SF, Huber-Spitzy V, Bohler K, et al. Ocular side effects associated with 13-cis-retinoic acid therapy for acne vulgaris: clinical features, alterations of tearfilm and conjunctival flora. Acta Ophthalmol Scand 1995;73:355-7
195. van Zwieten PA. Renewed interest in centrally acting antihypertensive drugs. Cardiovasc J S Afr 2000;11:225-9
196. Van Landuyt H, Joubert-Lequain I, Humbert P, et al. [Treatment of rosacea. Clonidine (0,075 mg/day) versus placebo (initial results). Ann Dermatol Venereol 1997;124:729
197. Pierard-Franchimont C, Quatresooz P,Pierard GE. Incidental control of rosacea by somatostatin. Dermatology 2003;206:249-51